Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.

Preventive vigabatrin has long-term epilepsy benefits in kids with sclerosis

16 Dec 2019
Multiple Sclerosis (MS) is a debilitating disease, in which nerve damage affects communications between the brain and body. HSCT could provide the therapeutic answer for MS patients.

Preventive treatment with antiepileptic agents in infants with tuberous sclerosis complex helps improve epilepsy control in the long-term, a recent study has found.

Researchers conducted a prospective, nonrandomized clinical trial on 14 infants with tuberculosis sclerosis complex. Preventive vigabatrin medication was initiated upon the detection of epileptic discharges on serial electroencephalography. Long-term outcomes were compared against a parallel group of 31 infants who received medication only after the onset of clinical seizures.

In the arm that received preventive medication, the median intelligence quotient (IQ) was 94, while 21 percent (n=14) of the participants had moderate or severe intellectual disabilities. Two children in this group had no consent for IQ assessment but nevertheless showed no evidence of epileptogenesis or seizures. They also appeared to have normal cognitive development and were able to attend regular primary school without special needs.

In the comparator group, the median IQ was 46, and 72 percent were diagnosed with intellectual disability. Six (24 percent) had severe and three (12 percent) had profound disability.

Comparison between groups revealed a significant benefit in favour of preventive treatment, both in terms of neuropsychologic measures (p<0.03) and the prevalence of intellectual disability (p=0.003).

The same was true for epilepsy outcomes. At the final follow-up visit, almost all of those who received standard medication developed clinical seizures, as opposed to only half in the preventive-treatment group (96 percent vs 50 percent; p=0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.